+1,090.9%
IBKR vs GSK
+115.7%
+975.2%
-63.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.9% | -0.1% | -5.8% | -5.8% |
| 7D | -13.0% | -5.3% | -7.6% | -11.0% |
| 30D | -16.6% | -3.7% | -12.9% | -15.5% |
| 3M | -20.7% | -7.3% | -13.4% | -18.6% |
| 6M | -14.9% | -4.2% | -10.6% | -14.6% |
| YTD | +11.0% | +0.9% | +10.2% | +8.0% |
| 1Y | +16.1% | +7.3% | +8.9% | +9.9% |
| 3Y | +265.9% | +52.7% | +213.1% | +180.0% |
| 5Y | +292.2% | +40.1% | +252.1% | +206.5% |
| 10Y | +699.4% | +98.7% | +600.7% | +397.6% |
| All | +1,090.9% | +115.7% | +975.2% | +451.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling